MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

MDT

82.86

-5.69%↓

VEEV

213.67

-3.6%↓

A

100.51

-8.39%↓

HQY

76.5

-7.7%↓

PDCO

30.94

-0.83%↓

Search

Erasca Inc

Fechado

1.16 -4.13

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.11

Máximo

1.17

Indicadores-chave

By Trading Economics

Rendimento

-1M

-32M

EPS

-0.11

Funcionários

103

EBITDA

1.5M

-35M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+313.22% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

19M

432M

Abertura anterior

5.29

Fecho anterior

1.16

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Erasca Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

5 de abr. de 2025, 09:30 UTC

Ganhos

Elon Musk's Mr. Fix-It Takes Center Stage During a Really Bad Week -- WSJ

5 de abr. de 2025, 01:00 UTC

Aquisições, Fusões, Aquisições de Empresas

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ

5 de abr. de 2025, 01:00 UTC

Aquisições, Fusões, Aquisições de Empresas

How BlackRock's Larry Fink Won Over Donald Trump -- WSJ -2-

4 de abr. de 2025, 21:53 UTC

Conversa de Mercado

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

4 de abr. de 2025, 21:44 UTC

Principais Notícias
Aquisições, Fusões, Aquisições de Empresas

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

4 de abr. de 2025, 21:00 UTC

Principais Notícias

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

4 de abr. de 2025, 20:52 UTC

Conversa de Mercado

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

4 de abr. de 2025, 20:52 UTC

Principais Notícias

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

4 de abr. de 2025, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

4 de abr. de 2025, 20:48 UTC

Principais Notícias

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

4 de abr. de 2025, 20:45 UTC

Principais Notícias

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

4 de abr. de 2025, 20:32 UTC

Principais Notícias

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

4 de abr. de 2025, 20:21 UTC

Principais Notícias

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

4 de abr. de 2025, 20:00 UTC

Principais Notícias

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

4 de abr. de 2025, 19:51 UTC

Conversa de Mercado

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

4 de abr. de 2025, 19:37 UTC

Principais Notícias

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

4 de abr. de 2025, 19:32 UTC

Conversa de Mercado

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

4 de abr. de 2025, 19:28 UTC

Principais Notícias

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

4 de abr. de 2025, 19:15 UTC

Conversa de Mercado

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

4 de abr. de 2025, 19:12 UTC

Principais Notícias

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

4 de abr. de 2025, 19:11 UTC

Conversa de Mercado

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

4 de abr. de 2025, 19:09 UTC

Conversa de Mercado

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

4 de abr. de 2025, 19:09 UTC

Principais Notícias

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

4 de abr. de 2025, 19:00 UTC

Conversa de Mercado

Fed Has Limited Options to Counter Tariffs -- Market Talk

4 de abr. de 2025, 18:53 UTC

Conversa de Mercado

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

4 de abr. de 2025, 18:51 UTC

Conversa de Mercado

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 de abr. de 2025, 18:44 UTC

Conversa de Mercado

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

Comparação entre Pares

Variação de preço

Erasca Inc Previsão

Preço-alvo

By TipRanks

313.22% parte superior

Previsão para 12 meses

Média 5 USD  313.22%

Máximo 6 USD

Mínimo 4 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Erasca Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

5

Comprar

0

Manter

0

Vender

Pontuação Técnica

By Trading Central

1.04 / 1.49Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bearish Evidence

Longo Prazo

Strong Bearish Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.